Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-2 and Abatacept in Frontotemporal Disorders
NCT06395038Phase 1Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- May 2024
- Primary completion
- Apr 2026
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of aldesleukin and abatacept in frontotemporal degeneration (FTD) (2 arms), sponsored by Houston Methodist Research Institute. Primary endpoint: Safety and Tolerability of Abatacept plus IL-2 at 6 months. Started May 2024; status: recruiting.
02
Drugs
aldesleukinabatacept
03
Conditions
frontotemporal degeneration (FTD)
Beyond the preview
Go deeper on NCT06395038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395038.